APA (7th ed.) Citation

Champiat, S., Lebbe, C., Baurain, J., Italiano, A., Sakkal, M., Spring-Giusti, C., . . . Cassier, P. (2024). 1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors. Annals of Oncology, 35, S692. https://doi.org/10.1016/j.annonc.2024.08.1083

Chicago Style (17th ed.) Citation

Champiat, S., et al. "1024P Initial Clinical Results of BT-001, an Oncolytic Virus Expressing an Anti-CTLA4 MAb, Administered as Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors." Annals of Oncology 35 (2024): S692. https://doi.org/10.1016/j.annonc.2024.08.1083.

MLA (9th ed.) Citation

Champiat, S., et al. "1024P Initial Clinical Results of BT-001, an Oncolytic Virus Expressing an Anti-CTLA4 MAb, Administered as Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors." Annals of Oncology, vol. 35, 2024, p. S692, https://doi.org/10.1016/j.annonc.2024.08.1083.